Theralink Technologies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THER research report →
Companytheralink.com
Theralink Technologies, Inc. , a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development.
- CEO
- Michael I. Ruxin
- IPO
- 2010
- Employees
- 16
- HQ
- Golden, CO, US
Price Chart
Valuation
- Market Cap
- $615.15K
- P/E
- -0.00
- P/S
- 1.01
- P/B
- -0.00
- EV/EBITDA
- -2.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 79.20%
- Op Margin
- -1479.80%
- Net Margin
- -5093.56%
- ROE
- 147.47%
- ROIC
- 48.92%
Growth & Income
- Revenue
- $606.80K · 6.85%
- Net Income
- $-30,907,505 · -142.43%
- EPS
- $-0.50 · -127.27%
- Op Income
- $-8,979,367
- FCF YoY
- -7.55%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.99
- Avg Volume
- 61.63K
Get TickerSpark's AI analysis on THER
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 29, 22 | Busch Jeffrey | other | 88,424,286 |
| Apr 22, 23 | Busch Jeffrey | other | 44,314,286 |
| Nov 29, 22 | Busch Jeffrey | other | 15,714,286 |
| Nov 29, 22 | Busch Jeffrey | other | 0 |
| Apr 22, 23 | Busch Jeffrey | other | 0 |
| Nov 29, 22 | Holley Danica | other | 17,029,905 |
| Nov 29, 22 | Holley Danica | other | 2,100,840 |
| Nov 29, 22 | Holley Danica | other | 0 |
| Nov 29, 22 | Holley Danica | other | 0 |
| Nov 29, 22 | Schwartz Matthew Wilson | other | 34,571,111 |
Our THER Coverage
We haven't published any research on THER yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THER Report →